R2-PURE (GHRP-2) by Meditech is a pharmaceutical-grade Growth Hormone Releasing Peptide-2 formulated as a lyophilized injectable peptide at 5 mg per vial. GHRP-2 is a synthetic hexapeptide growth hormone secretagogue with an established research history in neuroendocrinological and peptide pharmacology literature, investigated for its capacity to stimulate endogenous growth hormone secretion through ghrelin receptor activation. GHRP-2 is distinguished from its structural analogue GHRP-6 in comparative peptide research by its more potent GH stimulation profile and comparatively reduced appetite-stimulating activity, representing a pharmacologically distinct secretagogue option within the GHRP compound class.
 
✔ Key Research Insights
Studied for its role as a potent ghrelin receptor agonist, with documented stimulation of pituitary somatotroph GH release in research subjects via activation of the growth hormone secretagogue receptor (GHS-R1a) in neuroendocrinological research, noted for greater GH stimulation potency relative to GHRP-6 in comparative peptide pharmacology literature
Investigated for its downstream effects on IGF-1 production following GH stimulation, with associated influences on lean mass parameters and tissue repair mechanisms documented in peptide pharmacology observations
Researched for its influence on metabolic parameters and body composition indices in clinical observations, mediated through growth hormone secretagogue activity in documented subject populations
Examined for its effects on recovery markers, sleep architecture quality, and connective tissue parameters including joint and tendon health across peptide research literature
Documented for its comparatively reduced appetite-stimulating activity relative to GHRP-6 in comparative GHRP pharmacology research, attributed to differences in peripheral ghrelin receptor activation profiles between the two compounds
Researched for its mild cortisol and prolactin stimulatory effects, noted in comparative GHRP research as intermediate between the non-selective profile of GHRP-6 and the highly selective profile of ipamorelin in neuroendocrinological literature
Manufactured by Meditech to pharmaceutical-grade purity and lyophilized peptide formulation standards
 
📦 Product Specifications
Manufacturer: Meditech
Product: R2-PURE
Molecule: Growth Hormone Releasing Peptide-2 (GHRP-2)
Concentration: 5 mg per vial
Appearance: Lyophilized white powder
Form: Injectable peptide requiring reconstitution prior to administration
Dosage considerations may vary. Consulting a qualified professional is recommended.
 
⚙ How It Works
GHRP-2 is a synthetic hexapeptide that functions as an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a) — the ghrelin receptor — located on pituitary somatotroph cells and in the hypothalamus. In research subjects, binding of GHRP-2 to GHS-R1a produces two complementary effects on the growth hormone axis: direct stimulation of pituitary somatotroph cells to release endogenous growth hormone, and suppression of somatostatin — the endogenous inhibitor of GH release — at the hypothalamic level, resulting in amplified net GH output relative to baseline in documented pharmacological research. GHRP-2 has been documented in comparative GHRP pharmacology research to produce a more potent GH stimulation response per microgram administered relative to GHRP-6, while exhibiting a comparatively attenuated appetite-stimulating effect — a distinction attributed to differential peripheral ghrelin receptor activation profiles between the two compounds in neuroendocrinological research. Mild concurrent elevation of cortisol and prolactin has been documented in GHRP-2 research literature at higher doses, representing a pharmacological consideration of clinical relevance in research protocols requiring hormonal selectivity. The resulting elevation of circulating growth hormone subsequently stimulates hepatic IGF-1 production, with downstream effects on protein synthesis, cellular regeneration, fat metabolism, and recovery parameters documented across peptide pharmacology research literature. GHRP-2 is frequently examined in combination research protocols with GHRH analogues such as CJC-1295, as the complementary receptor pathways — GHS-R1a and GHRH receptor respectively — have been documented for potentially synergistic effects on pituitary GH output in comparative combination peptide research. Reconstitution with bacteriostatic water is standard protocol prior to subcutaneous administration in documented research settings, with lyophilized storage ensuring peptide stability and bioactivity prior to use.
 
⭐ Product Overview
Manufactured by Meditech to pharmaceutical-grade purity and lyophilized peptide formulation standards
Potent GHS-R1a agonist with a well-documented GH stimulation profile and comparatively attenuated appetite-stimulating activity relative to GHRP-6 in comparative GHRP pharmacology research
Pharmacologically intermediate selectivity profile between non-selective GHRPs and highly selective ipamorelin, as documented in comparative neuroendocrinological research literature
Frequently examined in combination protocols with GHRH analogues for potentially synergistic pituitary GH stimulation effects documented in comparative peptide pharmacology research
Widely referenced in neuroendocrinological and peptide pharmacology research under the GHRP-2 and growth hormone secretagogue designations
Available in lyophilized vial format requiring reconstitution prior to subcutaneous administration per standard peptide research protocols